These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Trends in research in developing new type of vaccines--aiming at efficacy and safety. Prevention and therapy of herpes simplex]. Kino Y Nihon Rinsho; 1987 Oct; 45(10):2380-3. PubMed ID: 3448273 [No Abstract] [Full Text] [Related]
4. Recombinant rabies vaccines: efficacy assessment in free-ranging animals. Rupprecht CE; Hanlon CA; Niezgoda M; Buchanan JR; Diehl D; Koprowski H Onderstepoort J Vet Res; 1993 Dec; 60(4):463-8. PubMed ID: 7777337 [TBL] [Abstract][Full Text] [Related]
5. Experimental treatments for HIV-infected patients. Am Fam Physician; 1989 Jun; 39(6):330. PubMed ID: 2729046 [No Abstract] [Full Text] [Related]
6. Oral vaccination of dogs with recombinant rabies virus vaccines. Rupprecht CE; Hanlon CA; Blanton J; Manangan J; Morrill P; Murphy S; Niezgoda M; Orciari LA; Schumacher CL; Dietzschold B Virus Res; 2005 Jul; 111(1):101-5. PubMed ID: 15896409 [TBL] [Abstract][Full Text] [Related]
7. [Recombinant replication-defective adenovirus based rabies vaccine]. Li WH; Zhang Y; Wang SH; Liu L; Yang F Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Dec; 25(6):650-4. PubMed ID: 14714304 [TBL] [Abstract][Full Text] [Related]
8. Vaccines for lyssaviruses other than rabies. Nel LH Expert Rev Vaccines; 2005 Aug; 4(4):533-40. PubMed ID: 16117710 [TBL] [Abstract][Full Text] [Related]
9. The development of therapeutic vaccines of the management of malignant melanoma. Dalgleish AG; Souberbielle BE Cancer Surv; 1996; 26():289-319. PubMed ID: 8783580 [No Abstract] [Full Text] [Related]
10. Web alert. Molecular, viral and cell-based vaccines for disease prevention and therapy. Stephens AC Curr Opin Mol Ther; 2004 Feb; 6(1):6-7. PubMed ID: 15011774 [No Abstract] [Full Text] [Related]
11. Deliberate release of a recombinant vaccinia-rabies virus for vaccination of wild animals against rabies. Pastoret PP; Brochier B; Coppens P Microb Releases; 1993 Mar; 1(4):191-5. PubMed ID: 8281357 [TBL] [Abstract][Full Text] [Related]
12. Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies. Weyer J; Rupprecht CE; Mans J; Viljoen GJ; Nel LH Vaccine; 2007 May; 25(21):4213-22. PubMed ID: 17434244 [TBL] [Abstract][Full Text] [Related]
13. [Immune response of mice to replication-defective recombinant adenovirus containing glycoprotein gene of rabies virus 3aG strain]. Li W; Zhang Y; Wang S Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Mar; 15(1):61-5. PubMed ID: 12526306 [TBL] [Abstract][Full Text] [Related]
15. Target and non-target effects of a recombinant vaccinia-rabies virus developed for fox vaccination against rabies. Pastoret PP; Brochier B; Boulanger D Dev Biol Stand; 1995; 84():183-93. PubMed ID: 7796953 [No Abstract] [Full Text] [Related]
16. Live vaccinia-rabies virus recombinants, but not an inactivated rabies virus cell culture vaccine, protect B-lymphocyte-deficient A/WySnJ mice against rabies: considerations of recombinant defective poxviruses for rabies immunization of immunocompromised individuals. Lodmell DL; Esposito JJ; Ewalt LC Vaccine; 2004 Sep; 22(25-26):3329-33. PubMed ID: 15308356 [TBL] [Abstract][Full Text] [Related]
17. New directions in vaccine research. Emerson D Minn Med; 2002 Feb; 85(2):18-22. PubMed ID: 11876095 [No Abstract] [Full Text] [Related]
18. Will we have and why do we need an Ebola vaccine? Klenk HD Nat Med; 2000 Dec; 6(12):1322-3. PubMed ID: 11100112 [No Abstract] [Full Text] [Related]